CSL Seqirus Signs Agreement to Localize Influenza Vaccine Manufacturing in Saudi Arabia
I'm PortAI, I can summarize articles.
CSL Seqirus, a subsidiary of CSL Limited, has signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to localize the manufacturing of cell-based seasonal and pandemic influenza vaccines. The agreement includes collaboration with Vaccine Industrial Company to produce vaccines at a new facility in Sudair City, expected to start operations in 2028. It also covers the establishment of pre-pandemic vaccine stockpiles and an Advance Purchase Agreement for pandemic vaccines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments